What are the CDC guidelines on the prevention and management of maternal chorioamnionitis?

Updated: May 08, 2018
  • Author: Fayez M Bany-Mohammed, MD; Chief Editor: Ted Rosenkrantz, MD  more...
  • Print

The Centers for Disease Control and Prevention (CDC) continues to publish updated guidelines for prevention of perinatal GBS disease; the most recent one was published in 2010, [170]  with an update in 2012. [171]

Although it was not considered a consensus development conference, in 2016, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) convened a panel of experts from the Society for Maternal-Fetal Medicine (SMFM), the American College of Obstetricians and Gynecologists (ACOG), and the American Academy of Pediatrics (AAP) for a workshop that issued a report on the evaluation and management of women and newborns with a maternal diagnosis of chorioamnionitis. [2] The panel noted that the term "chorioamnionitis" has been used to label a heterogeneous array of conditions characterized by intrauterine infection, inflammation, or both, with a consequent great variation in clinical practice for mothers and their newborns. Therefore, the panel proposed to replace the term "chorioamnionitis" with a more general, descriptive term: “intrauterine inflammation or infection or both,” abbreviated as “triple I.” The panel also proposed a classification (see the table under Diagnostic Considerations) for triple I as well as recommended approaches for the evaluation and management of pregnant women and their newborns with a diagnosis of triple I. Furthermore, the panel indicated the importance of recognizing that an isolated maternal fever is not synonymous with chorioamnionitis.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!